Ocular Therapeutix Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
10.6%projected annual EPS growth
Analyst Coverage
11analysts covering
FY Revenue (est.)
$52.9Mnext fiscal year
FY EPS (est.)
-$1.43next fiscal year
Monitoring Framework
Key Performance Indicators
Total Net Revenue Quarterly10.8M
Cash and Cash Equivalents Quarterly666.7MTarget: Sufficient to fund operations into 2028
SOL-R Phase 3 Trial Randomization Count Annually631
Watch Items
- AXPAXLI NDA Submission in Wet AMDTrigger: FDA formal discussions and alignment on SOL-1 Week 52 dataAction: Submit NDA under the 505(b)(2) regulatory pathway
- SOL-R Phase 3 Non-Inferiority Trial Topline DataTrigger: First Quarter of 2027 (1Q 2027)Action: Analyze and present topline efficacy and safety results
- HELIOS-3 Phase 3 Trial in Diabetic RetinopathyTrigger: Ongoing clinical milestones and enrollment updatesAction: Monitor patient recruitment and safety profiles
Research as of 19 Jun 2026